Vistagen to present at the jefferies 2025 global life sciences conference new york

South san francisco, calif.--(business wire)--vistagen (nasdaq: vtgn), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at jefferies 2025 global life sciences conference in new york. vistagen's president and chief executive officer, shawn singh, will participate in a fireside chat on thursday, june 5, at 11:40 a.m. ea.
VTGN Ratings Summary
VTGN Quant Ranking